Bio-Techne To Host Conference Call On October 30, 2018 To Announce First Quarter 2019 Financial Results
MINNEAPOLIS, Oct. 11, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, October 30, 2018 at 8:00 a.m. CDT to review first quarter 2019 financial results.
Access to the discussion may be obtained as follows:
Time: 8:00 a.m. CDT
Date: October 30, 2018
Dial-in: 1-866-548-4713 or 1-323-794-2093 (for international callers)
Conference ID: 2296266
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call. To access the recording, U.S. callers should dial 1-844-512-2921 or international callers should dial 1-412-317-6671 and enter the replay access code 2296266. The recording can also be accessed by going to:
The replay will be available from 11:00 a.m. CDT on Tuesday, October 30, 2018 until 11:00 p.m. CDT on Friday, November 30, 2018.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide.
Contact: David Clair, Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-october-30-2018-to-announce-first-quarter-2019-financial-results-300729255.html
SOURCE Bio-Techne Corporation